Resources
What we have published — and what we would want to read if we were choosing a CRO
Twenty-five peer-reviewed papers, engineering case studies with the numbers attached, and a vendor-neutral checklist we wrote for people evaluating us against everyone else.
Start here
Three ways to check whether we can actually do the thing you need.
Peer-reviewed
25 publications, 2016–2026
Crystal structures, ITC, SPR and DSC from work co-authored by Abwiz scientists. Eight of them are written up in plain language, with the measured numbers and the caveats.
Browse the publications →Case studies
What the platform has actually delivered
Campaign write-ups with affinities, timelines and developability data — including the step that did not work the first time.
See the case studies →Free PDF · no form
The Antibody Discovery CRO Buyer’s Checklist
Ten questions to ask any discovery CRO before you sign. Written to be used against us as well as against our competitors.
Get the checklist →Find the paper that matches your problem
Each of these is a published result, a plain-language write-up of what the data actually shows, and the service that runs the same work for you.
| If your problem is… | The published evidence | The service |
|---|---|---|
| Telling one phosphorylation site from another, one residue apart | Structural mechanisms behind high affinity and selectivity in phospho-specific antibodiesCrystallography and ITC on two rabbit mAbs | Phospho- and PTM-specific antibodies → |
| Distinguishing methylation states on the same lysine | Structural basis for antigen recognition by methylated lysine-specific antibodiesFour crystal structures; why the tightest binder is not always the right one | Phospho- and PTM-specific antibodies → |
| Reading a sulfation or glycan modification site-selectively | Specific recognition mechanism of an antibody to sulfated tyrosineSite-selective recognition of sulfated CCR5 | Carbohydrate, glycan and sulfation antibodies → |
| A single-domain antibody that aggregates or will not stay in solution | Improving the solubility of single domain antibodies using VH-like hallmark residuesDSC in defined buffers; the paper reports no usable affinity, and we say so | Developability optimization → |
| A clone that will not survive formulation or shipping | Roles of the disulfide bond between the variable and constant domains of rabbit immunoglobulinDirection only — this page states what is not recoverable from the paper | Thermostability engineering → |
| An epitope on a flexible loop that will not hold still | Antibody recognition of complement factor H reveals a flexible loopA VHH binding a floppy loop at picomolar KD | VHH / single-domain discovery → |
| A lead that stopped working when the target drifted | Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization21/21 variants neutralized; ~1,000× slower off-rate | STEM™ affinity maturation → |
| A cell-surface target with no commercial antibody in existence | Prospective isolation of mouse and human hematopoietic stem cells using PLXDC2A new antibody that became a new marker | Membrane and difficult-antigen discovery → |
Featured — a biobetter, including the part that did not work first time
Humanized, pH-sensitive infliximab engineered with STEM™
Higher potency and better developability in the same molecule. The write-up includes the self-association liability that maturation alone did not remove, and the targeted CDR substitution that fixed it.
Read the case study →Protocols and downloads
Support material for people already working with our catalog antibodies.
None of these answer your question?
Describe the target and what has already failed. A PhD scientist reads it — not a sales rep. You will get a straight answer within two business days about what looks tractable and what does not.
Tell us what you are working on → Or email info@abwizbio.com directly.